Sugi Predict

Sugi Predict / Targets / S1PR4

S1PR4

Sphingosine 1-phosphate receptor 4 · O95977 · S1PR4 on Sugi Atlas →

111,784 patent compounds predicted against S1PR4, 56,978 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL78519 SCHEMBL78519 0.53 10/20
SCHEMBL19906 SCHEMBL19906 0.68 9/20
SCHEMBL33472 SCHEMBL33472 0.68 9/20
SCHEMBL35167 SCHEMBL35167 0.68 9/20
SCHEMBL107866 SCHEMBL107866 0.68 9/20
SCHEMBL110008 SCHEMBL110008 0.68 9/20
SCHEMBL60775 SCHEMBL60775 0.56 9/20
SCHEMBL37361 SCHEMBL37361 0.49 9/20
SCHEMBL81356 SCHEMBL81356 0.56 8/20
SCHEMBL79372 SCHEMBL79372 0.53 8/20
SCHEMBL86694 SCHEMBL86694 0.53 8/20
SCHEMBL86989 SCHEMBL86989 0.53 8/20
Fingolimod Fingolimod (SCHEMBL7445) 1.00 7/20
Fingolimod Fingolimod (SCHEMBL81362) 0.97 7/20
SCHEMBL80476 SCHEMBL80476 0.72 7/20
SCHEMBL80477 SCHEMBL80477 0.70 7/20
SCHEMBL79788 SCHEMBL79788 0.51 7/20
SCHEMBL96583 SCHEMBL96583 0.49 7/20
SCHEMBL82307 SCHEMBL82307 0.46 7/20
SCHEMBL86789 SCHEMBL86789 0.38 7/20

Clinical trials — most relevant to S1PR4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis PHASE4WITHDRAWN
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study PHASE4COMPLETED
Sphingosine-1-phosphate and Pneumonia PHASE2/PHASE3UNKNOWN
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS PHASE3COMPLETED
Repurposing Siponimod for Alzheimer's Disease PHASE2RECRUITING
Fingolimod in Schizophrenia Patients PHASE2COMPLETED
Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI) PHASE2WITHDRAWN
Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation PHASE2ENROLLING_BY_INVITATION
A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers. PHASE1COMPLETED
Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis PHASE1COMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia nanUNKNOWN
Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod nanCOMPLETED
Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis nanUNKNOWN
Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study nanUNKNOWN
Vulvodynia: Identification of Potential Relevant Biomarkers nanCOMPLETED
Identification of Biomarkers and Molecular Targets Involved on Intervertebral Disc Degeneration and Discogenic Pain nanUNKNOWN
Studying Lipids as Potential Biomarkers in Patients With Fabry Disease nanCOMPLETED
Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma nanSUSPENDED
Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness nanUNKNOWN
Investigation of Inflammation Using [C-11]-CS1P1 nanACTIVE_NOT_RECRUITING
Evaluating the Association Between Sphingolipid Metabolites and Post-hepatectomy Liver Failure nanCOMPLETED
Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies nanCOMPLETED
Effect of Plasma Ceramides on Peripheral Vascular Function nanCOMPLETED
Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes nanCOMPLETED
Study of Neuroinflammation in Multiple Sclerosis by PET-MRI Imaging Using the Radiotracer ([18F]-DPA-714) : a Multicentre Cohort Study (INFLANET) nanRECRUITING
Efficacy and Safety of Yishen Daluo Yin Granule for Relapsing-Remitting Multiple Sclerosis nanNOT_YET_RECRUITING
Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma nanRECRUITING
Ceramide Level as Apredictor of Outcomes in Patients of Anterior Myocardial Infarction Undergoing Primary Coronary Intervention nanUNKNOWN
The ASTERS Study: Assessing the Role of Sphingolipids in AcuTE Respiratory Distress Syndrome (ARDS) nanCOMPLETED
PRIMUS : Real World Usage for Real World Evidence of CDSS Use in Multiple Sclerosis nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a S1PR4 binder may also engage these)

ProteinNameSimilarity
Q9Z0L1 — 0.993 Q9Z0L1 →
LPAR2 Lysophosphatidic acid receptor 2 0.975 landscape →
S1PR5 Sphingosine 1-phosphate receptor 5 0.975 landscape →
Q91X56 — 0.975 Q91X56 →
P47752 — 0.974 P47752 →
Q7TQN7 — 0.974 Q7TQN7 →
P11617 — 0.974 P11617 →
Q7TQP2 — 0.973 Q7TQP2 →
Q95KH4 — 0.972 Q95KH4 →
Q684M3 — 0.972 Q684M3 →
HTR6 5-hydroxytryptamine receptor 6 0.971 landscape →
Q6TLI7 — 0.971 Q6TLI7 →
Q9JKM5 — 0.971 Q9JKM5 →
P79393 — 0.970 P79393 →
Q60613 — 0.969 Q60613 →
NMUR1 Neuromedin-U receptor 1 0.969 landscape →
P35375 — 0.969 P35375 →
S1PR2 Sphingosine 1-phosphate receptor 2 0.969 landscape →
P52592 — 0.968 P52592 →
CNR2 Cannabinoid receptor 2 0.967 landscape →
Q9JL06 — 0.967 Q9JL06 →
Q96P69 — 0.966 Q96P69 →
P70597 — 0.966 P70597 →
Q80T02 — 0.966 Q80T02 →
PTGIR Prostacyclin receptor 0.966 landscape →
Q80SS6 — 0.964 Q80SS6 →
Q63384 — 0.964 Q63384 →
ADRB3 Beta-3 adrenergic receptor 0.964 landscape →
P43253 — 0.964 P43253 →
P30543 — 0.964 P30543 →